Abstract:
:Transdermal nicotine delivery systems are a cigarette smoking cessation aid designed to deliver nicotine into the systemic circulation via the skin. The partial replacement of plasma nicotine, which would have otherwise been obtained from cigarettes, reduces the severity of nicotine withdrawal symptoms, and so allows the smoker to abstain from smoking more easily. The systems are available in 16- and 24-hour application regimens, and are recommended for daily use for up to 20 weeks, including a series of 'weaning-off' courses. Clinical trials have shown that abstinence rates of 30 to 41% can be achieved during the first 6 weeks of application of transdermal nicotine systems, compared with 4 to 21% with placebo systems. The use of concomitant behavioural therapy may increase the success of treatment, with initial abstinence rates of up to 86% reported. However, long term abstinence rates (greater than 6 months) are considerably lower with or without behavioural therapy, often falling to less than half of the initial rates. Transdermal nicotine systems have been well tolerated in clinical trials, with local irritation at the site of application being the most common adverse event. Mild gastric, central nervous system (CNS) and sleep disturbances have also been reported. The ease of use and unobtrusive nature of the systems have resulted in a high degree of patient compliance. Thus, transdermal nicotine systems offer a convenient form of nicotine replacement therapy which are well tolerated and, due to their pharmacokinetic profile, probably have a low dependency potential. The short term abstinence rates achieved with this therapy are encouraging; however, the maintenance of abstinence in the long term is harder to achieve. Transdermal nicotine replacement therapy, therefore, represents an important advance in the difficult area of smoking cessation management.
journal_name
Drugsjournal_title
Drugsauthors
Palmer KJ,Buckley MM,Faulds Ddoi
10.2165/00003495-199244030-00011subject
Has Abstractpub_date
1992-09-01 00:00:00pages
498-529issue
3eissn
0012-6667issn
1179-1950journal_volume
44pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::The incidence of multiresistance in Gram-positive cocci causing infections in critically ill patients admitted to the intensive care unit (ICU) has increased notably in recent years. Thus, therapeutic proposals have been modified according to the emergence of multiresistant cocci and adapted to epidemiological markers...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200666060-00003
更新日期:2006-01-01 00:00:00
abstract::The efficacy of tropisetron in the prevention of nausea and vomiting induced by chemotherapy of varying emetogenic potential was evaluated in 545 patients with a variety of malignancies who had either proved refractory to antiemetic treatment during previous chemotherapy courses or who were considered to be at high ri...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-199200433-00007
更新日期:1992-01-01 00:00:00
abstract::Kaposi's sarcoma is the most common malignancy associated with HIV infection, and the morbidity and mortality attributable to AIDS-related Kaposi's sarcoma (AIDS-KS) may be increasing. No curative therapy is available for AIDS-KS, but palliative therapy can eliminate or reduce cosmetically unacceptable lesions, reduce...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199448040-00006
更新日期:1994-10-01 00:00:00
abstract::This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D₃/D₂/D₁ dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson's disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a trans...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0377-y
更新日期:2015-04-01 00:00:00
abstract::Macitentan (Opsumit(®)) is an orally active, dual endothelin receptor antagonist (ERA) with tissue targeting properties. Macitentan was approved recently in the EU (as monotherapy or combination therapy) for the long-term treatment of pulmonary arterial hypertension (PAH) in adults of WHO functional class II or III, a...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0266-9
更新日期:2014-09-01 00:00:00
abstract::The pharmacological treatment of epilepsy has made considerable progress during the last decade, due to improved knowledge of the clinical pharmacology of individual drugs, acquisition of new information on the factors affecting response and need for drug treatment, and development of promising new agents. Once a clin...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199549050-00004
更新日期:1995-05-01 00:00:00
abstract::It is well documented that long term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of peptic ulcer and that gastroduodenal mucosal erosions can be demonstrated in volunteers within 1 week of treatment initiation. However, long term studies in nonsurgical patients have not documented g...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199200445-00006
更新日期:1992-01-01 00:00:00
abstract::Pinacidil is a newly developed antihypertensive vasodilator, proposed to belong to the new group of smooth muscle relaxants, the K+ channel openers. The in vitro effects of pinacidil on induced tone, smooth muscle membrane potential and 86Rb and 42K efflux from rat resistance vessels (internal diameter about 200 micro...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198800367-00006
更新日期:1988-01-01 00:00:00
abstract::Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin 10 mg/day (vs p...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767001-00005
更新日期:2007-01-01 00:00:00
abstract::Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eve...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200565030-00005
更新日期:2005-01-01 00:00:00
abstract::Sitagliptin (Januvia, Glactiv(R), Tesavel(R)) is a dipeptidyl peptidase-4 inhibitor indicated for the treatment of type 2 diabetes mellitus. Oral sitagliptin as monotherapy or combination therapy was generally well tolerated and improved glycaemic control in well designed clinical trials in patients with type 2 diabet...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11203790-000000000-00000
更新日期:2010-03-05 00:00:00
abstract::Locally advanced prostate cancer (LAPC) is a heterogeneous entity usually embracing T3-4 and/or pelvic lymph-node-positive disease in the absence of established metastases. Outcomes for LAPC with single therapies have traditionally been poor, leading to the investigation of adjuvant therapies. Prostate cancer is a hor...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11591500-000000000-00000
更新日期:2011-05-28 00:00:00
abstract::The use of digitalis in congestive heart failure with normal sinus rhythm is still debated. While older uncontrolled, withdrawal studies from 1969 to 1983 provided incomplete data, with poorly documented clinical status and poor haemodynamic and exercise data, some patients did improve clinically when digitalis treatm...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199855060-00002
更新日期:1998-06-01 00:00:00
abstract::Nadroparin calcium is a low molecular weight heparin with a mean molecular weight of 4.5 kD. Compared with unfractionated heparin, nadroparin calcium has a greater ratio of anti-factor Xa/anti-factor IIa activity. Nadroparin calcium has a longer half-life and greater bioavailability than unfractionated heparin and can...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199244050-00010
更新日期:1992-11-01 00:00:00
abstract::Pharmacotherapy for the management of obesity is primarily aimed at weight loss, weight loss maintenance and risk reduction, and has included thyroid hormone, amphetamines, phentermine, amfepramone (diethylpropion), phenylpropanolamine, mazindol, fenfluramines and, more recently, sibutramine and orlistat. These agents...
journal_title:Drugs
pub_type: 杂志文章,meta分析,评审
doi:10.2165/00003495-200565100-00006
更新日期:2005-01-01 00:00:00
abstract::Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and diseas...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0860-8
更新日期:2018-01-01 00:00:00
abstract::An association between low serum potassium concentrations and ventricular arrhythmias has been observed by a number of investigators in patients with both acute myocardial infarction and symptomatic angina. The increased frequency of ventricular fibrillation in patients with low serum potassium concentrations has not ...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198600314-00014
更新日期:1986-01-01 00:00:00
abstract::Lung tissue remodelling in chronic inflammatory lung diseases has long been regarded as a follow-up event to inflammation. Recent studies have indicated that, although airway and lung tissue remodelling is often independent of inflammation, it precedes or causes inflammation. None of the available therapies has a sign...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0319-0
更新日期:2015-01-01 00:00:00
abstract::Intravenous peramivir (Alpivab™; Rapivab®; Rapiacta®; PeramiFlu®), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0981-8
更新日期:2018-09-01 00:00:00
abstract::For patients with superficial bladder tumours intravesical treatment or prophylaxis with thiotepa, doxorubicin, mitomycin C or Bacillus Calmette-Guerin has added a useful dimension to management, although the precise indications for each regimen remain to be better defined. For patients with metastatic bladder cancer ...
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-198938020-00009
更新日期:1989-08-01 00:00:00
abstract::The benefits of the treatment of hypertension currently consist of a substantially reduced incidence of premature stroke, left ventricular failure and malignant hypertension. The benefits for the individual are most clearcut in those who have already had severe or symptomatic hypertension. Older subjects who have a hi...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198800366-00003
更新日期:1988-01-01 00:00:00
abstract::Health behaviors such as retention in HIV medical care and adherence to antiretroviral therapy (ART) pose major challenges to reducing new HIV infections, addressing health disparities, and improving health outcomes. Andersen's Behavioral Model of Health Service Use provides a conceptual framework for understanding ho...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-015-0373-2
更新日期:2015-04-01 00:00:00
abstract::This review focuses on the biochemical and clinical aspects of methylation in neuropsychiatric disorders and the clinical potential of their treatment with ademetionine (S-adenosylmethionine; SAMe). SAMe is required in numerous transmethylation reactions involving nucleic acids, proteins, phospholipids, amines and oth...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199448020-00002
更新日期:1994-08-01 00:00:00
abstract::Rheumatoid arthritis is a disease of unknown aetiology characterised by persistent joint swelling, functional disability and increased mortality. No curative therapy exists at present but some therapeutic agents, commonly referred to as disease-modifying drugs, offer the potential for suppression of the inflammatory a...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199856030-00003
更新日期:1998-09-01 00:00:00
abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666020-00002
更新日期:2006-01-01 00:00:00
abstract::In human lung tissue in vitro, nedocromil sodium inhibited the release of histamine and leukotrienes induced by anti-IgE, as well as the contraction of isolated bronchi which followed this challenge. In the hamster cheek pouch in vivo, nedocromil sodium inhibited the inflammatory response induced by challenge with eit...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198900371-00013
更新日期:1989-01-01 00:00:00
abstract::Acarbose delays digestion of complex carbohydrates and disaccharides to absorbable monosaccharides, by reversibly inhibiting alpha-glucosidases within the intestinal brush border, thereby attenuating postprandial blood glucose peaks. Clinical trials have demonstrated that acarbose generally improves glycaemic control ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199346060-00007
更新日期:1993-12-01 00:00:00
abstract::Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an e...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/11208080-000000000-00000
更新日期:2011-10-22 00:00:00
abstract::In recent years, there have been major advances in the management of rheumatoid arthritis (RA), leading to the development of tumour necrosis factor (TNF) antagonists. With these agents, it is possible to arrest joint damage and, by treating early in the disease course, to prevent joint damage. It is also now thought ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666140-00001
更新日期:2006-01-01 00:00:00
abstract::Glaucoma, a group of progressive optic neuropathies with similar patterns of tissue loss, is primarily treated with medical therapy, followed by laser therapy and, later, incisional surgery. Aside from the introduction of prostaglandin analogs, topical carbonic anhydrase inhibitors, and topical alpha-agonists in the 1...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01130-z
更新日期:2019-07-01 00:00:00